A validated chiral chromatographic method for the enantiomeric separation of acalabrutinib.
Sign Up to like & getrecommendations! Published in 2022 at "Chirality"
DOI: 10.1002/chir.23485
Abstract: Acalabrutinib is aided in the treatment of various cancers, which acts by inhibiting Bruton tyrosine kinase. Acalabrutinib belongs to the imidazopyrazine class consisting of a chiral carbon, resulting in two enantiomers. Currently, no methods exist… read more here.
Keywords: validated chiral; acalabrutinib; chromatographic method; chiral chromatographic ... See more keywords
Cost-Effectiveness of Acalabrutinib Monotherapy Compared with Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-137688
Abstract: Introduction: Acalabrutinib is a highly selective, irreversible, next-generation, Bruton tyrosine kinase inhibitor (BTKi) approved for the treatment of patients with chronic lymphocytic leukemia (CLL). Acalabrutinib and ibrutinib are the only BTKis approved for the treatment… read more here.
Keywords: acalabrutinib monotherapy; treatment; acalabrutinib; cost effectiveness ... See more keywords
Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.7501
Abstract: 7501Background: Bruton tyrosine kinase (BTK) is a clinically validated target in WM. Acalabrutinib is a highly selective, potent, covalent BTK inhibitor that we evaluated in a Phase 2 study of pts ... read more here.
Keywords: waldenstr macroglobulinemia; pts waldenstr; acalabrutinib; acalabrutinib patients ... See more keywords
Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Elevate-TN four-year follow up.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.7509
Abstract: 7509Background: Early results from ELEVATE-TN (NCT02475681) at a median follow-up of 28.3 mo demonstrated superior efficacy of acalabrutinib (A) ± obinutuzumab (O) compared with O + chlorambucil (C... read more here.
Keywords: obinutuzumab chlorambucil; obinutuzumab versus; acalabrutinib; acalabrutinib obinutuzumab ... See more keywords
Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2021-0602
Abstract: Bruton's tyrosine kinase inhibitors have changed the treatment landscape for chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and lymphoplasmacytic lymphoma dramatically. In 2019, acalabrutinib was approved by the US FDA for the treatment of treatment-naive and… read more here.
Keywords: lymphocytic leukemia; acalabrutinib use; chronic lymphocytic; acalabrutinib ... See more keywords
Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.668162
Abstract: Bruton tyrosine kinase (BTK) is a validated target for treatment of B-cell malignancies, and oral inhibitors of BTK have emerged as a standard of care for these diseases. Acalabrutinib is a second generation, highly selective,… read more here.
Keywords: acalabrutinib; inhibitor; cell malignancies; treatment ... See more keywords